证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为1.99%，近年资本回报率不强。公司 业绩具有周期性。去年的净利率为1.19%，算上全部成本后，公司产品或服务的附加值不高。从历史年 报数据统计来看，公司近10年来中位数ROIC为2.03%，中位投资回报较弱，其中最惨年份2023年的 ROIC为-2.04%，投资回报极差。公司历史上的财报相对一般，公司上市来已有年报13份，亏损年份2 次，显示生意模式比较脆弱。商业模式：公司业绩主要依靠研发及营销驱动。需要仔细研究这类驱动力 背后的实际情况。 据证券之星公开数据整理，近期兄弟科技(002562)发布2025年中报。截至本报告期末，公司营业总收入 18.11亿元，同比上升3.45%，归母净利润6454.1万元，同比上升357.17%。按单季度数据看，第二季度 营业总收入8.92亿元，同比下降4.16%，第二季度归母净利润4363.29万元，同比上升10.96%。本报告期 兄弟科技短期债务压力上升，流动比率达0.89。 本次财报公布的各项数据指标表现尚佳。其中，毛利率18.42%，同比增25.45%，净利率3.56%，同比增 341.88%，销售费用、 ...

Core Viewpoint - Aoxiang Pharmaceutical (603229) reported a decline in net profit and revenue for the first half of 2025, indicating challenges in financial performance compared to the previous year [1] Financial Performance Summary - Total revenue for H1 2025 was 482 million yuan, a decrease of 2.14% year-on-year [1] - Net profit attributable to shareholders was 169 million yuan, down 5.83% year-on-year [1] - In Q2 2025, total revenue was 175 million yuan, reflecting an 8.48% decline year-on-year [1] - Q2 net profit was 50.15 million yuan, a significant drop of 25.54% year-on-year [1] Key Financial Metrics - Gross margin stood at 58.16%, a decrease of 2.76% year-on-year [1] - Net margin was 35.14%, down 3.77% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 38.91 million yuan, accounting for 8.07% of revenue, a slight increase of 0.13% year-on-year [1] - Earnings per share (EPS) was 0.20 yuan, a decrease of 9.09% year-on-year [1] - Cash flow per share was 0.05 yuan, down 16.7% year-on-year [1] Asset and Liability Overview - Cash and cash equivalents increased to 1.147 billion yuan, a rise of 15.89% year-on-year [1] - Accounts receivable decreased to 280 million yuan, down 8.62% year-on-year [1] - Interest-bearing debt rose to 331 million yuan, an increase of 64.41% year-on-year [1] Investment Return Metrics - The company's return on invested capital (ROIC) for the previous year was 7.79%, indicating average capital returns [3] - Historical median ROIC since listing is 11.16%, suggesting generally good investment returns [3] Debt Servicing Capability - The company maintains a healthy cash asset position, indicating strong debt servicing capability [3] Accounts Receivable Concern - The accounts receivable to profit ratio has reached 135.48%, suggesting potential issues in collection efficiency [4] Analyst Expectations - Analysts project 2025 earnings to be around 271 million yuan, with an average EPS forecast of 0.33 yuan [4]

据证券之星公开数据整理，近期奥锐特（605116）发布2025年中报。截至本报告期末，公司营业总收入 8.22亿元，同比上升12.5%，归母净利润2.35亿元，同比上升24.55%。按单季度数据看，第二季度营业 总收入4.2亿元，同比上升6.31%，第二季度归母净利润1.15亿元，同比上升8.53%。本报告期奥锐特盈 利能力上升，毛利率同比增幅5.42%，净利率同比增幅10.72%。 建议关注公司债务状况（有息资产负债率已达24.8%） 本次财报公布的各项数据指标表现尚佳。其中，毛利率60.11%，同比增5.42%，净利率28.58%，同比增 10.72%，销售费用、管理费用、财务费用总计1.59亿元，三费占营收比19.38%，同比增9.01%，每股净 资产5.93元，同比增15.89%，每股经营性现金流0.53元，同比增28.71%，每股收益0.58元，同比增 26.09% 证券之星价投圈财报分析工具显示： 业务评价：公司去年的ROIC为13.26%，资本回报率强。去年的净利率为24.04%，算上全部成本后，公 司产品或服务的附加值高。从历史年报数据统计来看，公司上市以来中位数ROIC为13.26%，投资回 ...

证券之星消息，根据企查查数据显示海思科（002653）公布了一项国际专利申请，专利名为"一种喹唑 啉酮衍生物的晶型及其制备方法和应用"，专利申请号为PCT/CN2025/077968，国际公布日为2025年8月 28日。 专利详情如下： 图片来源：世界知识产权组织（WIPO） 今年以来海思科已公布的国际专利申请24个。结合公司2025年中报财务数据，今年上半年公司在研发方 面投入了3.42亿元，同比增59.22%。 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The company has received the approval notice for the listing application of the chemical raw material drug Difluprednate from the National Medical Products Administration (NMPA) [1][3] - Difluprednate is a topical corticosteroid used to suppress inflammation caused by various irritants, primarily available in the form of eye drops for treating inflammation and pain related to eye surgeries [2][3] - The global sales figures for Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024, indicating a potential market opportunity for the company [3] Group 2 - The approval of the raw material drug will enhance the company's product portfolio and leverage its integrated advantages in raw material and formulation production, aiding in business expansion [4] - The company has invested approximately 2.6 million yuan in the research and development of the Difluprednate raw material project [3]

2023 2024 2025 ■ 营业总收入-中报(亿) ■ 单季度营业总收入-第二季度(亿) 一 归母净利润 - 归母净利润-中报(万) -3619.31 同比 -195.74% 单季度归母净利润-第二季度(万) -3806.13 同比 -535.20% 6925.19 3780.14 2881.97 874.56 -3619.33 3806.12 2023 2024 ■ 归母净利润-中报(万) ■ 单季度归母净利润-第二季度(万) 一 扣非净利润 一 扣非净利润-中报(万) -4484.80 同比 -242.47% 单季度扣非净利润-第二季度(万) -4258.53 同比 -821.03% 5602.88 3147.86 1960.23 590.61 -4484.79-4258.52 2023 2025 2024 ■ 扣非净利润-中报(万) ■ 单季度扣非净利润-第二季度(万) l 财务数据 销售毛利率 (%) 36.41 同比 -25.16% 证券之星消息，润都股份2025年中报显示，公司主营收入5.48亿元，同比下降8.22%；归母净利 润-3619.31万元，同比下降195.75%；扣非净利润-44 ...

Core Viewpoint - The report provides a detailed account of the fundraising activities and the usage of funds by 博瑞生物医药 (Suzhou) Co., Ltd. as of June 30, 2025, highlighting the amounts raised, their allocation, and the management of these funds [1][2][3]. Fundraising Overview - The company raised a total of RMB 521.11 million from its initial public offering (IPO) in 2019, with a net amount of RMB 439.98 million after deducting various fees [1]. - In 2022, the company issued convertible bonds amounting to RMB 465 million, resulting in a net amount of RMB 456.83 million after fees [2]. - The company also raised RMB 226.61 million through a private placement of shares in November 2022, with the net amount after fees not specified [2]. Fund Management - The company established a dedicated account for managing the raised funds, ensuring that the funds are used specifically for their intended purposes [3]. - A tripartite supervision agreement was signed with the underwriter and banks to oversee the management of the funds [3]. Fund Usage and Balance - As of June 30, 2025, the total amount of funds used from the IPO was RMB 455.75 million, with a remaining balance of RMB 0.00 million [5]. - For the convertible bonds, RMB 466.75 million was used, leaving no remaining balance [5]. - From the private placement, RMB 188.74 million was utilized, with a remaining balance of RMB 3.64 million [13]. Project Adjustments - The company did not make any adjustments to the investment amounts for the projects funded by the IPO as of June 30, 2025 [5]. - The overseas high-end formulation drug production project was delayed, with the expected completion date pushed from December 2021 to June 2023 due to various factors including the pandemic [5]. - The company has also changed the implementation entities for some projects to improve management efficiency [5]. Temporary Idle Funds - The company has not used idle funds to temporarily supplement working capital as of June 30, 2025 [8]. - The company has engaged in cash management for temporarily idle funds, generating a total return of RMB 15.62 million from such activities [10][12].

Company Performance - Haixiang Pharmaceutical reported a revenue of approximately 925 million yuan for the first half of 2025, representing a year-on-year decrease of 10.94% [1] - The net profit attributable to shareholders of the listed company was approximately 14.09 million yuan, down 63.01% year-on-year [1] - Basic earnings per share were 0.01 yuan, reflecting a year-on-year decrease of 50% [1] Industry Context - The news highlights the competitive landscape in the automotive sector, with nearly 120 brands and 1,600 vehicles participating in the upcoming A-class car exhibition in Southwest China [1] - The event is expected to reshape the market dynamics for new energy vehicles, referred to as the "third pole" in the industry [1]

Group 1 - The company announced a change in registered capital and amendments to its Articles of Association, which will be submitted for shareholder approval [1][4] - As of August 27, 2025, the company’s registered capital increased by 10,479.00 CNY due to the conversion of "Haoyuan Convertible Bonds" into 10,479 shares [1] - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, resulting in an increase of 648,570 shares and registered capital by 648,570.00 CNY [2] - The company reduced its total share capital by 47,725 shares and registered capital by 47,725.00 CNY due to the cancellation of compensation shares related to performance commitments [3] - The company completed the registration for the second vesting period of the 2023 restricted stock incentive plan, increasing total share capital by 527,660 shares and registered capital by 527,660.00 CNY [4] - The total share capital changed from 210,959,781 shares to 212,098,765 shares, and registered capital changed from 210,959,781.00 CNY to 212,098,765.00 CNY [4] Group 2 - The company plans to amend its Articles of Association to reflect changes in registered capital and total share capital, in accordance with relevant laws and regulations [4] - The specific amendments to the Articles of Association include updates to the registered capital and total share capital clauses [4]

Meeting Details - The fifth meeting of the supervisory board of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. was held on August 28, 2025, with a notification sent on August 18, 2025 [1] - The meeting was attended by 2 out of 3 supervisors, with one supervisor represented by proxy [1] Resolutions Passed - The supervisory board approved the half-year report for 2025, ensuring that the report does not contain any false records, misleading statements, or significant omissions [1][2] - The board also approved a change in accounting policy aimed at improving the alignment of revenue recognition criteria with the ERP information management system, ensuring more reliable and accurate financial information [2]